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e  assessed reported adherence to antiretroviral (ARV) pro-
hylaxis  by HIV-exposed infants followed in the Eunice Kennedy
hriver  National Institute of Child Health and Human Devel-
pment  (NICHD) International Site Development Initiative
NISDI)  Longitudinal Study in Latin American Countries
LILAC) protocol1 through at least 6–12 weeks of life. LILAC
s  a prospective cohort study at sites in Argentina, Brazil, and
eru  which enrolled in 2008 and 2009. Among infants enrolled
t  birth, the primary caregiver was  interviewed at birth and at
very infant visit regarding infant adherence to ARVs during
he  previous three days, timing of last dose missed of any pre-
cribed  ARV, and any problems or situations making it difﬁcult
or  caregivers to give infants the prescribed ARV(s).
Of  the 385 infants prescribed ARVs at enrollment, per-
ent  adherence could be calculated for 312 infants (i.e., those
ith  at least two days of available adherence data). Of these
12  infants, 309 (99.0%) had perfect adherence; 99% received
idovudine. Reasons cited for not having perfect adherence
ere:  the maternity nurse did not administer the ARV(s) to
he  infant (n = 1), the caregiver forgot to give the ARV(s) (n = 1),
nd nausea (n = 1). At the 6–12 week visit, 115 (30.6%) infants
ad  a current prescription for ARVs. Percent adherence could
e  calculated for 97 infants at this visit, of whom 92 (94.8%) had
erfect  adherence. Caregivers of nine infants (8.0%) reported
he  last dose missed of any prescribed ARV was  within the
revious  two weeks, six (5.3%) within the previous month,
nd  two (1.8%) over a month ago. The remaining 96 caregivers
85.0%)  reported no missed doses. Seventeen caregivers indi-
ated  difﬁculties in giving ARVs to the infants. Primary reasons
ited  were:  the caregiver forgot to give the ARV(s) (n = 5), the
nfant  was  sleeping (n = 2), the caregiver ran out of medica-
ion  (n = 2), and the caregiver misunderstood the prescription
n  = 2). Given the high proportion of subjects reporting perfect
dherence,  formal analyses of factors associated with lack of
dherence  were  not pursued.Our  results differ substantially from those of other studies
n  which lower adherence rates were reported from Africa2,3
62–73.1% adherence to a single dose of nevirapine at birth)and the U.S. (71% adherence to zidovudine in the week prior to
interview)4 using similar self-report methods. It is unclear why
higher  adherence was  observed in our population, although
a  higher susceptibility to social desirability bias is a possi-
bility.  Previous studies of adherence have demonstrated that
self-reported  adherence is generally higher than adherence
measured by pill count, electronic monitoring, or drug con-
centrations in the blood.5 Thus, adherence rates in this cohort
likely  represent an overestimate of the actual adherence.
In  conclusion, high levels of adherence to infant ARV pro-
phylaxis  were observed in this study. Infant ARV prophylaxis
adherence should be further evaluated in studies utilizing
additional measures of adherence in order to more  precisely
estimate adherence and understand factors predicting non-
adherence.
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Appendix  A.  The  NISDI  LILAC  Study  Team
Principal investigators, co-principal investigators, study coor-
dinators, coordinating center representatives, and NICHD
staff  include: Argentina: Buenos Aires: Marcelo H. Losso, Irene
Foradori, Alejandro Hakim, Erica Stankievich, Silvina Ivalo
(Hospital  General de Agudos José María Ramos Mejía); Brazil:
Belo  Horizonte: Jorge A. Pinto, Victor H. Melo, Fabiana Kakehasi,
Beatriz M. Andrade (Universidade Federal de Minas Gerais);Costamilan (Universidade de Caxias do Sul/Servic¸o  Munic-
ipal  de Infectologia); Nova Iguacu: Jose Pilotto, Luis Eduardo
Fernandes, Gisely Falco (Hospital Geral Nova de Iguacu – HIV
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Family Care Clinic); Porto Alegre: Rosa Dea Sperhacke, Breno
Riegel Santos, Rita de Cassia Alves Lira (Universidade de Cax-
ias  do Sul/Hospital Conceic¸ão);  Rosa Dea Sperhacke, Mario
Ferreira Peixoto, Elizabete Teles (Universidade de Caxias do
Sul/Hospital  Fêmina); Regis Kreitchmann, Luis Carlos Ribeiro,
Fabrizio Motta, Debora Fernandes Coelho (Irmandade da
Santa  Casa de Misericordia de Porto Alegre); Ribeirão Preto:
Marisa  M.  Mussi-Pinhata, Geraldo Duarte, Adriana A. Tira-
boschi Bárbaro, Conrado Milani Coutinho, Fabiana Rezende
Amaral,  Anderson Sanches de Melo (Hospital das Clínicas da
Faculdade de Medicina de Ribeirão Preto da Universidade de
São  Paulo); Rio de Janeiro: Ricardo Hugo S. Oliveira, Elizabeth
S. Machado, Maria C. Chermont Sapia (Instituto de Pueri-
cultura  e Pediatria Martagão Gesteira); Esau Custodio Joao,
Leon Claude Sidi, Maria Leticia Santos Cruz, Maria Isabel
Gouvêa, Mariza Curto Saavedra, Clarisse Bressan, Fernanda
Cavalcanti A. Jundi (Hospital dos Servidores do Estado); São
Paulo:  Regina Celia de Menezes Succi, Prescilla Chow (Escola
Paulista de Medicina-Universidade Federal de São Paulo); Peru:
Lima:  Jorge O. Alarcón Villaverde (Instituto de Medicina Trop-
ical “Daniel Alcides Carrión” – Sección de Epidemiología,
UNMSM), Carlos Velásquez Vásquez (Instituto Nacional Materno
Perinatal),  César Gutiérrez Villafuerte (Instituto de Medicina
Tropical  “Daniel Alcides Carrión” – Sección de Epidemiología,
UNMSM); Data Management and Statistical Center: Yolanda
Bertucci,  Rachel Cohen, Laura Freimanis Hance, René Gonin,
D.  Robert Harris, Roslyn Hennessey, James Korelitz, Margot
Krauss,  Sue Li, Karen Megazzini, Orlando Ortega, Sharon Soth-
ern  de Sanchez, Sonia K. Stoszek, Qilu Yu (Westat, Rockville,
MD,  USA); NICHD: George K. Siberry, Rohan Hazra, Lynne M.
Mofenson, Jennifer S. Read, Heather Watts (Eunice Kennedy
Shriver  National Institute of Child Health and Human Devel-
opment,  Bethesda, Maryland, USA). Supported by NICHD
Contract # N01-HD-3-3345 (2002–2007) and by NICHD Contract
#  HHSN267200800001C (NICHD Control #: N01-HD-8-0001)
(2007–2012).
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